Tech News
← Home  ·  All topics

Fda

21 GoKawiil briefs on this topic

Eight Sleep launches smaller Pod 6 with solo option starting at $1,999

Eight Sleep released its Pod 6 smart mattress cooling/heating device with a 50% smaller footprint and a new solo size for single sleepers, priced from $1,999 for solo and $2,699 for standard sizes. The company says the new pod adjusts temperature 20% faster and has 9x more sensors than the prior generation, letting it distinguish between two sleepers or ignore a pet or child on the bed. The device launches today in more than 37 countries and is compatible with existing accessories.

New AI regulation push ignores unenforced existing laws, critic argues

A wave of alarm over AI risks has spurred calls for new regulatory frameworks, from an FDA-style safety agency to bank-style supervision or even a development pause, with figures like Alex Bores and Bernie Sanders backing such proposals. The author argues that laws and regulators already exist to address many of AI's harms, but enforcement against powerful tech firms has been weak, raising doubts that new rules would fare any better.

Compounding pharmacies' glutathione IV drips sicken over 30 across four states

The CDC and FDA report that more than 30 people in four states developed bacterial toxin poisoning after receiving intravenous glutathione treatments at wellness clinics. Investigators traced the problem to at least two compounding pharmacies that used glutathione powder graded only for oral dietary supplements—sourced from Medisca Inc.—to prepare injectable drips, rather than the sterile grade required for injection.

Montana's SB535 lets clinics charge for post-Phase 1 experimental treatments

Montana has enacted SB535, a law that extends right-to-try provisions by allowing physicians to administer treatments that have cleared FDA Phase 1 trials outside formal clinical trials, provided a state-registered review board approves the protocol and care is delivered at a licensed clinic. Unlike federal right-to-try or expanded access rules, the Montana law permits sponsors and clinics to charge patients for these treatments, addressing what backers call the core funding gap facing biotech firms after early trials.

FDA Leadership Changes Spark Investor Return to Rare-Disease Biotech

Investors are reportedly re-entering rare-disease drug stocks after the departure of stricter FDA regulators under the Trump administration. The shift in agency leadership has reduced concerns about tougher approval hurdles that had previously discouraged investment in this biotech segment.

Broccoli Sprouts Recalled Over Salmonella Outbreak Sickening 22 in Four States

The FDA is investigating a multistate Salmonella outbreak linked to broccoli sprouts, which have been recalled from store shelves. So far, 22 people across four states have fallen ill, with two requiring hospitalization. Health officials are urging consumers not to eat any of the affected products.

Fall flu, COVID and RSV vaccines roll out largely as usual despite CDC turmoil

Despite chaos at the CDC's vaccine advisory panel and RFK Jr.'s anti-vaccine actions as health secretary, updated flu and COVID-19 vaccines have been FDA-approved and are already shipping to pharmacies for the fall season. Major insurers have agreed to keep covering previously recommended vaccines at no cost through at least 2027, and state health officials expect a mostly normal rollout.

Bill Ackman funds experimental mitochondrial transplant for daughter's vision loss

After his daughter Lucy suffered a brain hemorrhage that left her blind, billionaire Bill Ackman used his connections to secure her advanced care at Mount Sinai and pursue an experimental treatment. In May, the FDA granted her medical team first-time emergency authorization to transplant mitochondria from her leg muscle into her eyes in an attempt to repair her optic nerves. Ackman has since pledged over $400 million to establish an institute focused on longevity and brain health research.

Crystal Temptations recalls Chocolatey Eyeballs candy over undeclared allergen risk

Crystal Temptations issued a recall of its Chocolatey Eyeballs product after the FDA flagged a safety concern, reportedly tied to undisclosed allergens that could pose serious health risks. The candy was sold at major retailers including TJ Maxx and Marshalls across 13 states. The FDA has advised consumers who purchased the product to destroy it rather than consume or return it.

Circular unveils Ring 3 Pro and Slim smart rings with NFC payments

Circular has launched its Ring 3 series, succeeding last year's Ring 2, in two versions: a titanium Pro model retaining ECG-based AFib detection, and a lighter Slim model using biocompatible epoxy but lacking ECG tracking. Both rings add vibrating alerts for alarms and reminders and an NFC chip enabling contactless payments directly from the ring.

Revlimid successor daraxonrasib shrinks tumors in early lung cancer trial

A week after its US approval for advanced pancreatic cancer, the drug daraxonrasib has shown early promise against non-small cell lung cancer, the most common form of the disease. In a small trial published in the New England Journal of Medicine, tumors shrank in over 30% of patients whose cancers carried mutations in RAS family proteins and who had already failed other treatments. A larger randomized trial comparing daraxonrasib to standard chemotherapy is now underway.

FDA labels Whole Foods guacamole recall Class I over salmonella risk

The FDA has designated a recall of Mild Guacamole and Salsa Dips sold at Whole Foods Market as Class I, its most severe category, due to possible salmonella contamination. The recall, initiated August 7, covers 10 product varieties and nearly 13,000 units with best-by dates between August 7 and August 16, 2026, and is tied to contaminated jalapenos distributed nationwide by a Mexican supplier.